Download or read book New Rapid acting Antidepressants written by Kenji Hashimoto and published by Springer Nature. This book was released on 2021-10-22 with total page 152 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
Download or read book Rapid Acting Antidepressants written by and published by Academic Press. This book was released on 2020-06-29 with total page 404 pages. Available in PDF, EPUB and Kindle. Book excerpt: The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Download or read book Ketamine written by Kenji Hashimoto and published by Springer Nature. This book was released on 2020-03-05 with total page 189 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.
Download or read book Ketamine for Treatment Resistant Depression written by Sanjay J. Mathew and published by Springer. This book was released on 2016-11-25 with total page 167 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
Download or read book Ketamine written by and published by . This book was released on 2020 with total page 187 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants. --
Download or read book Ketamine for Treatment Resistant Depression written by Gustavo H. Vazquez and published by Academic Press. This book was released on 2020-09-16 with total page 170 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action
Download or read book Emergence of Ketamine as a Rapid Acting Antidepressant written by Preet Mohinder Singh Bedi and published by . This book was released on 2018 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ketamine is a phencyclidine derivative and N-methyl-D-aspartate receptor antagonist, widely popular as a dissociative anesthetic. Its use as an anesthetic in humans was progressively fallen out due to its associated adverse effects and the emergence of newer and safer anesthetics. In recent few decades, various reports related to its efficacy in the treatment of resistant depression with anti-suicidal potential draw significant attention from researchers around the globe. The rapid clinical effect of ketamine within hours as compared to traditional antidepressants that take several weeks makes it a hot topic in antidepressant research. Studies conducted in the recent past suggest its mechanism of action through glutamate modulation via receptors like NMDA, AMPA as well as downregulation of BDNF etc. This chapter will shed light on the various mechanisms of ketamine related to antidepressant activity. Along with that its pharmacokinetics, toxicology and ongoing clinical trials will also be discussed.
Download or read book Astrocytes in Psychiatric Disorders written by Baoman Li and published by Springer Nature. This book was released on 2021-12-09 with total page 368 pages. Available in PDF, EPUB and Kindle. Book excerpt: This contributed volume discusses the multiple roles of astrocytes, which determine the progression and outcome of neuropsychiatric diseases. This emerging area of study examines the ways in which astrocytes are involved in various aspects of disease initiation, progression and resolution. This monograph aims to integrate the body of information that has accumulated in recent years revealing the active role of astrocytes in neuropsychiatric pathology and in psychiatric disorders. Understanding roles of astrocytes in pathology will provide new targets for medical intervention and aid the development of much needed therapeutics. This book will be valuable for researchers and workers in the fields of neurobiology, neurology, and psychiatry, as well as fill the need for a textbook used in advanced courses/graduate seminars in glial pathophysiology.
Download or read book The NMDA Receptors written by Kenji Hashimoto and published by Springer. This book was released on 2017-02-08 with total page 153 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides a history of and an update on the functional status of the NMDA receptors. The NMDA receptors are essential for neuronal development, synaptic plasticity, learning, and cell survival. It covers molecular, cellular, anatomical, biochemical, and behavioral aspects, to highlight their distinctive regulatory properties, their functional significance, and their therapeutic potential in a number of diseases. A group of international experts discuss the development of NMDA receptors, their basic functions, and how they are implicated in a wide range of diseases including depression, psychosis, and pain.
Download or read book Next Generation Antidepressants written by Chad E. Beyer and published by Cambridge University Press. This book was released on 2010-05-20 with total page 151 pages. Available in PDF, EPUB and Kindle. Book excerpt: The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.
Download or read book Successful Drug Discovery Volume 1 written by János Fischer and published by John Wiley & Sons. This book was released on 2015-05-04 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first volume of the book series "Successful Drug Discovery" is focusing on new drug discoveries during the last decade, from established drugs to recently introduced drugs of all kinds: small-molecule-, peptide-, and protein-based drugs. The role of serendipity is analyzed in some very successful drugs where the research targets of the lead molecule and the drug are different. Phenotypic and target-based drug discovery approaches are discussed from the viewpoint of pioneer drugs and analogues. This volume gives an excellent overview of insulin analogues including a discussion of the properties of rapid-acting and long-acting formulations of this important hormone. The major part of the book is devoted to case histories of new drug discoveries described by their key inventors. Eight case histories range across many therapeutic fields. The goal of this book series is to help the participants of the drug research community with a reference book series and to support teaching in medicinal chemistry with case histories and review articles of new drugs.
Download or read book Clinical Psychopharmacology written by Nassir Ghaemi and published by Oxford University Press, USA. This book was released on 2019-01-04 with total page 601 pages. Available in PDF, EPUB and Kindle. Book excerpt: Clinical Psychopharmacology offers a comprehensive guide to clinical practice that explores two major aspects of the field: the clinical research that exists to guide clinical practice of psychopharmacology, and the application of that knowledge with attention to the individualized aspects of clinical practice. The text consists of 50 chapters, organized into 6 sections, focusing on disease-modifying effects, non-DSM diagnostic concepts, and essential facts about the most common drugs. This innovative book advocates a scientific and humanistic approach to practice and examines not only the benefits, but also the harms of drugs. Providing a solid foundation of knowledge and a great deal of practical information, this book is a valuable resource for practicing psychiatrists, psychiatric nurse practitioners, medical students and trainees in psychiatry, as well as pharmacists.
Download or read book Neurobiology of Depression written by Joao Luciano de Quevedo and published by Academic Press. This book was released on 2019-01-03 with total page 471 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neurobiology of Depression: Road to Novel Therapeutics synthesizes the basic neurobiology of major depressive disorder with discussions on the most recent advances in research, including the interacting pathways implicated in the pathophysiology of MDD, omics technologies, genetic approaches, and the development of novel optogenetic approaches that are changing research perspectives and revolutionizing research into depression. These basic foundational understandings on the neurobiology underlying the disorder, along with a comprehensive summary of the most recent advances in research are combined in this book to aid advanced students and researchers in their understanding of MDD. Depression is one of the most common mental-health disorders caused by a variety of genetic, biological, environmental and psychological factors. Major depressive disorder (MDD) is typically treated with first-line antidepressant agents that primarily target monoamine neurotransmission. However, only approximately one-third of patients with MDD achieve remission following a trial with such an antidepressant. Furthermore, MDD is a heterogeneous phenotype, and new frameworks, such as the NIMH Research Domain Criteria (RDoC) may provide a more accurate, biologically based comprehension of the symptomatic heterogeneity of this devastating illness. Aids readers in understanding major depressive disorder in the context of NIMH Research Domain Criteria (RDoC) recommendations Covers a range of existing and potential pharmacologic and non-pharmacologic treatment options, from lifestyle adjustments, to antidepressants and novel therapeutics Synthesizes discussions on the cellular and molecular mechanisms underlying symptoms with the clinical aspects of depression
Download or read book The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia written by American Psychiatric Association and published by American Psychiatric Pub. This book was released on 2016 with total page 220 pages. Available in PDF, EPUB and Kindle. Book excerpt: The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.
Download or read book Fluoxetine written by Graziano Pinna and published by . This book was released on 2015-04-01 with total page 412 pages. Available in PDF, EPUB and Kindle. Book excerpt: Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.
Download or read book Cognition in Major Depressive Disorder written by Roger S. McIntyre and published by OUP Oxford. This book was released on 2014-05-08 with total page 104 pages. Available in PDF, EPUB and Kindle. Book excerpt: Part of the Oxford Psychiatry Library (OPL) series, Cognition in Major Depressive Disorder provides a succinct summary of cognitive deficits reported in patients with major depressive disorder (MDD) with a particular focus on aspects of measurement, underlying disease pathophysiology, implications for treatment and prevention. This book also provides readers an opportunity for clinical-based assessment of cognition and recommendations for how cognitive measurement and treatment is positioned in the management of individuals with mood disorders.
Download or read book Pharmacokinetics and Adverse Effects of Drugs written by Ntambwe Malangu and published by BoD – Books on Demand. This book was released on 2018-05-23 with total page 164 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a fruit of a collaborative work from several international scientists. It will be a useful resource for researchers, students, and clinicians. Each individual chapter could serve as a prescribed reading for postgraduate students and clinicians specializing in and practicing clinical pharmacology and toxicology, pharmacotherapy and pharmacotherapeutics, pharmacovigilance, and toxicovigilance, as well as those involved in clinical research, drug discovery, and development. Every chapter in this book discusses and provides illustrations on the theme discussed based on authors' understanding and experience while summarizing existing knowledge. In doing so, each chapter provides a new insight that would benefit a novice as well as a seasoned reader in understanding the pharmacokinetic mechanisms and risk factors involved in the occurrence of adverse effects of drugs.
